13 reports

The drug candidates target the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • AstraZeneca PLC

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Asthma
  • Digestive System Disorder
  • United States
  • Product Initiative

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Asthma
  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Asthma
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • United Kingdom
  • United States
  • World
  • Product Initiative

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • Asthma
  • Ophthalmology
  • Therapy
  • Aldeyra Therapeutics, Inc.

About ## percent of people who have food allergies are allergic to more than one food.

  • Asthma
  • Monoclonal Antibody
  • Ophthalmology
  • Respiratory Disease
  • Therapy

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Ophthalmology
  • Respiratory Disease
  • Therapy
  • Product Initiative

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Infectious Disease
  • Monoclonal Antibody
  • Ophthalmology
  • SCYNEXIS, Inc.

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative

(allergy and autoimmune diagnostics) which was sold to Thermo Fisher Scientific (TMO) in September of 2011.

  • Ophthalmology
  • Research And Development
  • United States
  • Company
  • ProQR Therapeutics N.V.

The drug candidate is a ##-imino-##, ##, ##-thiadiazole derivative.

  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative